" class="no-js "lang="en-US"> ResInnova Labs - Medtech Alert
Sunday, July 20, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ResInnova Labs | Pharmtech Focus

ResInnova Labs

About ResInnova Labs

ResInnova Labs

ResInnova Laboratories is a Silver Spring, Maryland based Limited Liability Company owned and operated by Matthew Hardwick, Phd. ResInnova is a durability and microbiology testing laboratory. We primarily work with the apparel, healthcare, and hospitality industries.

Related Story

Diseases

 SARS-CoV-2

SARS-CoV-2, Influenza A Inactivated by Zinc-embedded Nylon Fabric

September 20 2021

An international team of scientists and engineers from the University of Cambridge, the Icahn School of […]